Recent Updates
Recently added Catalysts

GSK Biologicals' influenza vaccine GSK576389A

Phase 2

Influenza | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 8, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
ACTIVE_CONTROLLED
Total Trials1
Total Enrollment68
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00538473Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsPHASE2 COMPLETED 68Oct 23, 2007Dec 12, 2007Jun 8, 20181 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
During a 7-day follow-up period after vaccination

Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.

Duration of Solicited Local Symptoms
During a 7-day follow-up period after vaccination

Duration was expressed as median number of days any symptom persisted. Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: occurrence of any local symptom regardless of their intensity grade.

Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms
During a 7-day follow-up period after vaccination

Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 39°C. Related: symptom assessed by the investigator as causally related to the study vaccination.

Duration of Solicited General Symptoms
During a 7-day follow-up period after vaccination

Duration was expressed as median number of days any symptom persisted. Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: occurrence of any general symptom regardless of their intensity grade or relationship to vaccination.

Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
During a 21-day follow-up period after vaccination

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: occurrence of any unsolicited AE regardless of their intensity grade or relationship to vaccination. Grade 3: unsolicited AE that prevented normal everyday activities. Related: unsolicited AE assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)
During a 21-day follow-up period after vaccination

Medically Significant Conditions (MSCs) included all unsolicited adverse events that resulted in a medically attended visit. Any: occurrence of any MSC regardless of their intensity grade or relationship to vaccination. Grade 3: MSC that prevented normal everyday activities. Related: MSC assessed by the investigator as causally related to the study vaccination.

Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)
Throughout the entire study (up to Day 21)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any: occurrence of any SAE regardless of their relationship to vaccination. Related: SAE assessed by the investigator as causally related to the study vaccination.

Secondary Endpoints
Serum Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains
At Days 0 and 21
Number of Subjects Seropositive for HI Antibodies Against Each of the Three Vaccine Strains
At Days 0 and 21
Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains
At Day 21
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
FluAS25 (GSK576389A) GroupEXPERIMENTALSubjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
Fluarix GroupACTIVE_COMPARATORSubjects received 1 dose of Fluarix™.
Interventions
NameTypeDescription
GSK Biologicals' influenza vaccine GSK576389ABIOLOGICALSingle dose, intramuscular injection
Fluarix™BIOLOGICALSingle dose, intramuscular injection
Unlock Study Design Details
Eligibility Criteria
Age Range67 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Subjects who were previously vaccinated with GlaxoSmithKline Biologicals Fluarix™ or GSK576389A vaccines in the 107973 study (NCT00386113). * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the st...

Countries:Belgium
Unlock Eligibility Criteria